A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C. Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembe, Rolf Kaiser, Siow Ming Lee

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalLung Cancer
Volume120
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Nintedanib
  • Non-small cell lung cancer
  • Squamous
  • TRIPLE ANGIOKINASE INHIBITOR
  • CLINICAL-PRACTICE GUIDELINES
  • LABEL DOSE-ESCALATION
  • BIBF 1120
  • CONTROLLED-TRIAL
  • CARBOPLATIN
  • PACLITAXEL
  • BEVACIZUMAB
  • PHARMACOKINETICS
  • ANGIOGENESIS

Cite this

Forster, M., Hackshaw, A., De Pas, T., Cobo, M., Garrido, P., Summers, Y., Dingemans, A-M. C., Flynn, M., Schnell, D., von Wangenheim, U., Loembe, A-B., Kaiser, R., & Lee, S. M. (2018). A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3). Lung Cancer, 120, 27-33. https://doi.org/10.1016/j.lungcan.2018.03.007